What Has Been the Growth of the Insomnia Market So Far?
The insomnia market has seen considerable growth due to a variety of factors.
•The market size for insomnia has seen consistent growth in the past few years. It is projected to increase from $5 billion in 2024 to $5.24 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.7%.
The considerable growth during the historical period is due to factors such as rising stress levels, higher prevalence of mental health disorders, the impact of unusual work schedules and shift work, enhanced awareness and diagnosis, and increased intake of stimulants.
What Are the Future Growth Projections for the Insomnia Market?
The insomnia market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated strong expansion is on the cards for the insomnia market over the coming years, with projections suggesting a value of $6.62 billion in 2029, aligning with a compound annual growth rate (CAGR) of 6.0%.
Factors contributing to this growth in the forecast period are the effect of the global health crisis, increasing cognizance of good sleep habits, highlight on mental health and wellness, government-led sleep wellness initiatives, and social determinants' impact. Foreseen trends for this predicted period comprise digital solutions for sleep tracking, cognitive behavioral therapy devised for insomnia patients, utilizing telehealth for sleep-related consultations, instilling sleep health into primary healthcare, and introducing more research on new therapeutic targets.
Which Factors Are Boosting Growth In The Insomnia Market?
The increasing prevalence of work-related stress is anticipated to fuel the expansion of the insomnia market in the future. Work-related stress pertains to the damaging emotional and physical reactions that arise when job demands and pressures exceed an employee's resources, abilities, or knowledge. This type of stress can contribute to health deterioration, particularly insomnia. The intensity of insomnia determines the treatment approach, which can range from drugs to cognitive-behavioral therapies, among other interventions. Consequently, the rise in work-related stress is enhancing sales in the insomnia market. For instance, the American Psychological Association reported in October 2022 that persistent workplace stress is a looming issue, with 77% of workers admitting to experiencing job-related stress in the preceding month. Also, 57% acknowledged suffering from negative consequences like emotional exhaustion (31%), commonly associated with workplace burnout. Hence, the escalating work-related stress is promoting the development of the insomnia market.
What Key Areas Define The Segmentation Of The Global Insomnia Market?
The insomnia market covered in this report is segmented –
1) By Therapy Type: Non-Pharmacological Therapy, Pharmacological Therapy
2) By Drug Class: Anti-Depressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Non-Pharmacological Therapy: Cognitive Behavioral Therapy For Insomnia (CBT-I), Sleep Hygiene Education, Relaxation Techniques, Stimulus Control Therapy, Sleep Restriction Therapy
2) By Pharmacological Therapy: Prescription Medications, Over-The-Counter, Herbal Supplements
Pre-Book The Insomnia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Insomnia Market?
The central trend emerging in the insomnia market is product innovation. Key players in the therapeutic insomnia market are crafting novel treatments to maintain their market stance. For instance, the Korea-based medical device firm, WELT, secured approval from the Ministry of Food and Drug Safety (MFDS) for its advanced insomnia treatment gadget, WELT-I, in April 2023. WELT-I has been identified as an inventive medical tool designed to tackle behavioural, psychological, and cognitive elements that escalate or prolong insomnia. The device uses cognitive behavioural therapy (CBT) as a primary treatment according to insomnia clinical guidelines. It falls under the category of software as a medical device (SaMD), and it aims to ameliorate insomnia by tailoring sleep duration, examining sleep disruption patterns, stepping in to improve patient behaviour for better sleep quality, and providing relaxation therapy for eight weeks to mitigate tension and anxiety.
Who Are the Key Players in the Insomnia Market?
Major companies operating in the insomnia market include:
• Pfizer Inc.
• Merck & Co Inc.
• Sanofi S.A.
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Koninklijke Philips N.V.
• Viatris Inc.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Eisai Co.Ltd.
• UCLA Health Insomnia Clinic
• Jazz Pharmaceuticals PLC
• Aurobindo Pharma Limited
• Purdue Pharma LP
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Zydus Lifesciences Limited
• Lupin Limited
• Mallinckrodt Pharmaceuticals Plc.
• Fisher & Paykel Healthcare Corporation Limited
• ResMed Inc.
• Sunovion Pharmaceuticals Inc.
• Casper Sleep Inc.
• Biocodex Inc.
• Vanda Pharmaceuticals Inc.
• Pernix Therapeutics Holdings Inc.
• SleepScore Labs
• Alpha-Stim
• Neurim Pharmaceuticals Ltd.
• NightWare Inc.
What Is The Most Dominant Region In The Insomnia Market?
North America was the largest region in the insomnia market in 2024. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
